Novo Nordisk’s CagriSema Faces Setback in Obesity Drug Race
Novo Nordisk, the pharmaceutical giant behind the weight-loss medications Wegovy and Ozempic, encountered a significant challenge in its pursuit of leadership in the obesity treatment market. The company’s next-generation drug, CagriSema, failed to meet expectations in a pivotal clinical trial, according to a report from The Guardian. This outcome has raised questions about the drug’s potential to compete with existing treatments like Eli Lilly’s tirzepatide-based therapies.
Key Trial Results and Market Impact
The trial, which involved 809 participants, aimed to demonstrate that CagriSema would be at least as effective as tirzepatide, the active ingredient in Eli Lilly’s weight-loss drug Zepbound. However, the results showed that CagriSema achieved an average weight loss of 23% over 84 weeks, compared to 25.5% for tirzepatide. This shortfall led Novo Nordisk to state that the drug “did not achieve its primary endpoint of demonstrating non-inferiority” against the competitor.
The disappointing outcome sent shockwaves through the market, with Novo Nordisk’s shares dropping sharply. Analysts noted that the results could undermine the company’s strategy to maintain dominance in the weight-loss sector, particularly as its flagship product Wegovy faces patent expiration after 2030. As Yahoo Finance reported, the trial’s findings have left investors skeptical about CagriSema’s ability to outperform existing options.
Understanding CagriSema and Its Development
CagriSema, a weekly injection, combines cagrilintide—a synthetic version of the pancreatic hormone amylin—with semaglutide, the GLP-1 receptor agonist found in Wegovy and Ozempic. The dual-action mechanism was designed to suppress appetite and enhance satiety, potentially offering greater efficacy than single-component therapies. However, the trial results suggest that this approach did not surpass the benefits of tirzepatide, which is marketed as Zepbound in the U.S. And Mounjaro in Europe.
Novo Nordisk had positioned CagriSema as a successor to Wegovy, aiming to reassert its leadership in the $2 billion obesity drug market. The company’s CEO, Lars Fruergaard Jørgensen, had previously emphasized the drug’s potential